Quale sarebbe il prezzo per GBS Inc. (GBS)

Il prezzo per GBS Inc. (GBS) è $0.4732

Qual è la capitalizzazione di mercato per GBS Inc. (GBS)

La capitalizzazione di mercato per GBS Inc. (GBS) è $7.05M

GBS Inc. (GBS) Rendimento del Dividendo

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Anno	Rendimento da dividendi	Cambia
Non abbastanza dati per le date fornite.

Anno

Rendimento da dividendi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rendimento da dividendi	Il paese
Abbott Laboratories ABT.US	2.23%	US
Stryker Corporation SYK.US	1.03%	US
Medtronic plc MDT.US	3.69%	IE
Boston Scientific Corporation BSX.US	0.00%	US
Edwards Lifesciences Corporation EW.US	0.00%	US

Azienda

Rendimento da dividendi

Il paese